MedTrace Logo

Nevanac 3-Month Safety Study With QID Dosing

NCT00332774 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2012-03-05

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.

Conditions

  • Cataract

Interventions

DRUG

Nepafenac ophthalmic solution 0.1%

1 drop 4 times daily for 90 days

DRUG

Ketorolac Tromethamine ophthalmic solution 0.4%

1 drop 4 times daily for 90 days

OTHER

Nepafenac ophthalmic suspension vehicle

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Stephen Lane · Medical Monitor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332774 on ClinicalTrials.gov